Carmichael Hill & Associates’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Carmichael Hill & Associates’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$10.8K	Sell	432 -332	-43%	-$8.09K	﹤0.01%	577
2024 Q2	$14.3K	Buy	764 +232	+44%	+$4.35K	0.01%	524
2024 Q1	$10.5K	Sell	532 -248	-32%	-$4.84K	﹤0.01%	557
2023 Q4	$13.7K	Hold	780	–	–	0.01%	532
2023 Q3	$13.5K	Buy	780 +176	+29%	+$2.96K	0.01%	518
2023 Q2	$8.51K	Buy	604 +152	+34%	+$2.03K	﹤0.01%	580
2023 Q1	$4.86K	Buy	452 +180	+66%	+$2.37K	﹤0.01%	642
2022 Q4	$4.08K	Hold	272	–	–	﹤0.01%	641
2022 Q3	$3K	Buy	272 +24	+10%	+$273	﹤0.01%	718
2022 Q2	$2K	Hold	248	–	–	﹤0.01%	725
2022 Q1	$2K	Buy	+248	New	+$2.63K	﹤0.01%	751

Other funds holding KNSA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Carmichael Hill & Associates's KNSA Position: Q3 2024 in Review

Carmichael Hill & Associates reduced its Kiniksa Pharmaceuticals (KNSA) stake by 43% in Q3 2024, selling an estimated $8.09K and leaving 432 shares worth $10.8K. The position accounts for ﹤0.01% of the portfolio, ranked #577.

Carmichael Hill & Associates first reported a position in KNSA in Q1 2022 and has held it in 11 quarters since. The position peaked at $14.3K in Q2 2024. 176 funds tracked by Wall St. Rank hold KNSA as of Q3 2024.

Carmichael Hill & Associates held 432 shares of Kiniksa Pharmaceuticals worth $10.8K as of Q3 2024.
Carmichael Hill & Associates sold 332 Kiniksa Pharmaceuticals shares in Q3 2024, an estimated $8.09K.
Kiniksa Pharmaceuticals made up ﹤0.01% of Carmichael Hill & Associates's portfolio in Q3 2024, its #577 holding.
Carmichael Hill & Associates first reported a position in Kiniksa Pharmaceuticals in Q1 2022 and has held it in 11 quarters since.
Carmichael Hill & Associates's Kiniksa Pharmaceuticals position peaked at $14.3K in Q2 2024.
176 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2024.

Based on Carmichael Hill & Associates's 13F filing for Q3 2024, filed 29 Oct 2024.